Active ingredientEtomoxirCat. No. P-E137-001CAS 124083-20-1Family · Pharmaceutical analytical standards
Etomoxir
An irreversible inhibitor of the enzyme CPT-1, which stops fatty acids from entering mitochondria to be burned. Developed in Germany from 1980 for type 2 diabetes, it was later studied in heart failure in the early 2000s. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Today it is used in laboratories to 'switch off' fat burning in cells, including cancer cells; of its two mirror-image forms only one, the (R) form, blocks the enzyme.
Go to the active ingredient →Active ingredientEtomoxirCat. No. P-E137-001CAS 124083-20-1
Isotopically labelledEtomoxir-13C6Cat. No. P-E137-003
Isotopically labelledEtomoxir-d5Cat. No. P-E137-004
ImpurityEtomoxir sodium saltCat. No. P-E137-005CAS 828934-41-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.